Wound Management Technologies, Inc.’ CellerateRX® Featured In Clinical Research Session At The Symposium Of Advanced Wound Care (SAWC) In Las Vegas, NV

ADDISON, TX--(Marketwired - October 16, 2014) - Wound Management Technologies, Inc. (OTCQB: WNDM), an emerging commercial stage company with its primary product, a patent-protected and FDA-cleared collagen product, CellerateRX®, today announced that the product will be featured in an abstract accepted to the clinical research session at the Symposium of Advanced Wound Care (SAWC), which is being held at the Caesars Palace in Las Vegas, NV on October 16th - 18th, 2014.

The abstract titled "An Observational Longitudinal Retrospective Meta-Analysis Clinical Review of Hydrolyzed Type 1 Collagen in Wounds with Complex Comorbidities" will be presented by Dr. Eric Lullove on Friday, October 17th in Session CR018. The presentation will consist of research comparing the healing rate of diabetic ulcers, venous leg ulcers, and traumatic wounds.

Dr. Lullove is in private practice in Boca Raton, FL and serves as Medical Director for the West Boca Center for Wound Healing. His practice focuses on wound healing and limb preservation with research and clinical interests in diabetic foot ulcers, venous leg ulcers, chronic wounds, and peripheral arterial disease/critical limb ischemia.

"We are excited to be returning to SAWC for yet another year. We look forward to the data being presented on our advanced wound care collagen product, CellerateRX®, at the clinical research session this year. Our patients continue to benefit from the clinical efficacy and cost efficiency of CellerateRX®," comments Cathy Bradshaw, President of Wound Care Innovations.

Wound Care Innovations, a subsidiary of Wound Management Technologies, is also an exhibitor at SAWC in booth #502 in the Exhibit Hall. The symposium is considered the largest wound care conference in the country.

About Wound Management Technologies
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its Wound Care Innovations subsidiary's unique, patented collagen product line, CellerateRX®, which is FDA-cleared for all wound types except 3rd degree burns. The wound care products are reimbursable under Medicare Part B and the surgical products are reimbursed as part of a procedural billing. Wound Management has other advanced biotech products in development including a patented resorbable bone hemostat line that is in late stages of development. For more information visit www.wmgtech.com.

To download Wound Management Technologies' investor relations app, which offers access to SEC documents, press releases, audio casts and more, please visit https://itunes.apple.com/us/app/wound-management-technologies/id913690915?ls=1&mt=8 to download on your iPhone and iPad or https://play.google.com/store/apps/details?id=com.theirapp.woundmgmt for your Android mobile device.

Information about Forward-Looking Statements
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.